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Abstract 
Aims: Animal models show that a single dose of MDMA (‘ecstasy’) can result in long-term 
disruption of sleep. We evaluated the relationship between ecstasy consumption and the use 
of sleep medications in humans after controlling for key factors. 
Design The Personality and Total Health Through Life project uses a longitudinal cohort with 
follow-up every four years. This study reports data from waves two and three. 
Setting: Participants were recruited from the electoral roll in the Australian Capital Territory 
and Queanbeyan, New South Wales, Australia. 
Participants: Participants were aged 20-24 years at wave one (1999-2000). 
Measures: The study collected self-reported data on ecstasy, meth/amphetamine, cannabis, 
alcohol, tobacco and use of sleeping medications (pharmaceutical or other substances). 
Depression was categorised with the Brief Patient Health Questionnaire (BPHQ). Other 
psychosocial measures included lifetime traumas. We used generalised estimating equations 
to model outcomes. 
Results: Ecstasy data were available from 2128 people at wave two and 1977 at wave three: 
sleeping medication use was reported by 227 (10.7%) respondents at wave two and 239 
(12.1%) at wave three. Increased odds ratios (OR) for sleeping medication use was found for 
those with depression (OR=1.88, (95% confidence interval (CI) 1.39, 2.53), women 
(OR=1.44, 95% CI 1.13, 1.84), and increased by 19% for each lifetime trauma. Ecstasy use 
was not a significant predictor, but  >monthly versus never meth/amphetamine use increased 
the odds (OR=3.03, 95% CI 1.30, 7.03). 
Conclusion: The use of ecstasy was not associated with the use of sleeping medications 
controlling for other risk factors. 
  
Introduction 
‘Ecstasy’ (3,4-methylenedioxymethamhetamine, MDMA) is widely used, with an estimated 
10.5 to 25.8 million users globally (1). In Australia, the highest prevalence is among those 
aged 20-29 years where nearly 10% report using ecstasy in the last year (2). This 
consumption raises potential health concerns as the use of ecstasy appears to have long-
lasting impacts on serotonin function (3). Data from animal studies, including among non-
human primates, have indicated neurotoxic effects of MDMA on the serotonin 5-HT system 
at doses equivalent to those used by recreational ecstasy users (4-5). Potential serotonergic 
neurotoxicity has been implicated in depressed mood (6-8). However, pre-existing mental 
health disorders in stimulant users (9), environmental and genetic risk factors plus other 
demographic factors (e.g. unemployment, lower education) may also account for this 
association (10-11).  
 
Sleep disruption may account for, or in part account for, the increased levels of depressive 
symptomology often observed in ecstasy users. Sleep disruption is a prevalent symptom of 
mood disorder (12) and included in many measures of depression and emotional distress (13-
15). It is also a potential consequence of ecstasy use due to the pharmaceutical properties of 
the drug (16-17) or lifestyle factors associated with its use (18). Data from animal studies has 
shown that even a single exposure of 15mg/kg MDMA in rats can produce increased 
wakefulness and motor activity evident to 28 days (19) with some impacts on sleep function 
still evident at 180 days in rats (20). In a sample of social drug users, clinically important 
levels of sleep disturbance have been observed among ecstasy users after controlling for 
poly-drug use (21). However, findings regarding the persistent impacts of ecstasy use on 
sleep patterns in humans are inconsistent, and indicate that sleep differences between users 
and non-users may be pre-existing or due to other drug use (22). 
 Few ecologically valid studies of the relationship between ecstasy use and sleep disturbance 
have been conducted to investigate whether or not the data from the laboratory translates to 
external settings. Moreover, interpretation of these findings is complicated by (a) the exact 
constitution of ‘ecstasy’ consumed outside the laboratory, which may contain a range of other 
psychoactive substances in addition to MDMA, and (b), the co-use of alcohol and other drugs 
that also impact on sleep. The acute use of meth/amphetamine is expected to increase 
wakefulness and reduce the total amount of sleep, followed by a rebound period of extended 
sleep, and then a period of sleep disruption (23-24). Both cannabis and alcohol may initially 
appear to have sleep-inducing properties. However, tolerance develops to the sleep-inducing 
effect of cannabis (22) and alcohol increases the fragmentation of sleep, with alcohol 
withdrawal associated with considerable sleep disruption (24). A recent study by Ogeil and 
colleagues considered this issue by controlling for poly-drug use (21), but did not examine 
the potentially important, differential impacts of different categories of drugs. 
 
The aim of this study was to use prospective data from a representative, adult community 
cohort to examine the relationship between the ecstasy consumption and sleep problems, 
operationalised as the use of sleeping medications (pharmaceutical or other substances). To 
address the aforementioned limitations of former ecological studies these analyses will 
control for key factors, in particular, cannabis, meth/amphetamine hazardous/harmful use of 
alcohol and mood problems. Sleep disturbance is also associated with trauma and is one of 
the diagnostic features of post-traumatic stress disorder (12) so a measure of lifetime 
traumatic events was included too. Thus, the study will make a unique contribution in 
identifying whether or not the posited link between recreational use of ecstasy and depression 
is likely to be due to increased sleep problems. 
Method 
Sample 
The “Personality and Total Health Through Life Project” (PATH) is a cohort study that 
assesses adult lifespan changes in wellbeing, mental health, personality and cognitive 
function. At recruitment, the cohorts were aged 20-24, 40-44 and 60-64 years with follow-up 
conducted every four years. The recruitment process has previously been described in detail 
and the sample is largely representative of the 2001 Australian Census data for the Canberra 
(Australian Capital Territory) and Queanbeyan (New South Wales) area of Australia (25-26). 
The current paper focuses on the youngest cohort due to the low lifetime prevalence of 
ecstasy use in the other groups. At baseline (wave one), conducted in 1999-2000, 2404 
people were recruited; at wave two (2003-2004) there were 2139 (89%) re-interviews, 190 
refusals, seven people had died and 68 could not be contacted. At wave three, conducted in 
2007-2008, there were 1978 (82.3%) interviews, 272 refusals, 7 deaths and 51 could not be 
contacted and 96 had withdrawn at an earlier wave (see online Appendix A for STROBE 
diagram and check list). Ecstasy data were only collected at waves two and three. At both 
follow-ups, original  participants were contacted via telephone calls, visits to their last known 
address, e-mail contact, use of secondary contacts, electronic telephone database and the 
electoral roll. For those who had moved out of the area in-person interviews were arranged if 
possible, but overseas participants were asked to complete a postal/email survey. The original 
sample size was determined by factors including estimated prevalence of the principal 
disorders of interest and anticipated transition rates through the course of the study. All 
participants in the original study who met criteria for inclusion in the current study (i.e. 
answered the questions on the use of ecstasy at wave two) were included in analyses. 
Measures 
Sleep problems were defined as self-reported, current use of any sleeping medications (In the 
last month have you taken or used any pills or medications (including herbal remedies) to 
help you sleep). This approach has been used in previous epidemiological studies (27). Ever 
use of ecstasy was assessed with Have you ever tried any of the following Ecstasy (pills, eccy, 
XTC, MDMA). Those who endorsed this item were then asked if they had used ecstasy in the 
last 12 months (yes/no) and their frequency of use in this period (options: every day, once a 
week, about once a month, every few months, once or twice a year, less often, don’t currently 
use). The use of amphetamines for non-medical purposes (speed, go-ee, whiz, rev, crystal, 
meth, crystal meth, ice, shabu, batu, uppers, ox-blood, liquid speed) was assessed with the 
same pattern of questions and frequency of use options.  However, an error in the skip 
programming at wave three resulted in those who reported no ecstasy use in the last 12 
months not being asked for frequency data on their meth/amphetamine use: these people were 
included in the analysis as ‘frequency unknown’. Thus, at wave three there were 258 people 
(13% of the sample or 43% of those who had used meth/amphetamine) who reported 
meth/amphetamine use but not the frequency of use. Alcohol use was assessed with the 
Alcohol Use Disorders Identification Test (AUDIT) with those scoring 8 or greater classified 
as hazardous users (28). At wave three, question 3 of the AUDIT was modified to reflect the 
Australian Guidelines in place at the time (29): women were asked about consuming five or 
more standard drinks and men about consuming seven or more. Cannabis use was assessed 
using items from an existing survey and a two item screening test (30-31). Based on these 
questions participants were classified as either “never users”, “not current users” (last used 
more than 12 months prior to interview or reported “don’t currently use”) or “infrequent 
users” (used in the last 12 months, once or twice per year to every 1-4 months”), “>monthly” 
(used in the last 12 months, once per month to “once a week or more”). Ecstasy use was 
classified into the same categories, as was meth/amphetamine except as noted above, at wave 
three data on frequency was not collected for some cases. Smoking tobacco was classified as 
“current”, “former”, “never” smokers.  The presence of major or other depression was 
derived from the standard algorithm for the nine-item Brief Patient Health Questionnaire 
(BPHQ) (15) (e.g. “major depression”: question 1a or b and five or more of items a-h are 
“more than half the days” or item i endorsed: “other depression” as per major depression 
except endorsing two to four items.) Response options refer to feelings over the last two-
weeks and are: not at all, several days, more than half the days, nearly every day. The BPHQ 
gives a ‘provisional’ diagnosis: to make a formal diagnosis other causes must be ruled out 
such as bereavement, a history of manic episodes, physical illness, medications and drug use. 
Lifetime trauma was assessed with ten items adapted from the National Survey of Mental 
Health and Wellbeing and including combat experience, life threatening accident, natural 
disaster, rape, sexual molestation, serious assault, torture (32). Lifetime trauma was the sum 
of events prior to wave two, plus events between waves two and three. 
Analysis 
At baseline, socio-demographic and substance use variables were compared between groups 
(those who have never versus ever used ecstasy at wave two) using chi square analysis for 
differences in proportions, and t-tests for continuous measures. The respective descriptive 
statistics were numbers with percentages and means with standard deviations (SD). For the 
longitudinal analysis, generalised estimating equation (GEE) models were used (SPSS 
20.0.0). This approach overcomes many of the limitations of traditional repeated measures 
methods, in that it uses all available data without requiring substitution or estimation of 
missing values, whilst still accounting for non-independence of data from the same 
individuals. This avoids the exclusion of cases with non-complete data and does not assume 
homogeneity of correlations over waves of measurement (33). Akaike’s information criterion 
was used to select the covariance structure (lower values showing better fit). The analyses 
used binominal distributions with logit link, an unstructured correlation matrix and hybrid 
(Fisher plus Newton-Raphson) estimation. The model included substance use variables, 
lifetime trauma and socio-demographic variables that showed significant differences between 
users and non-users of ecstasy at wave two. The structure was specified with subject number 
as the repeated measure and wave the within subject variable. Cases with missing dependent 
variable or covariate data are excluded by GEE. The interaction of ecstasy and time was 
examined to explore whether differences in ecstasy use across waves was associated with 
differences in sleep. This interaction was not significant and is thus not reported in the 
results. Finally, logistic regression, with simultaneous entry of measures, was used to predict 
wave three sleeping medications from wave two data. 
Table 1 here 
Results 
Of the 2139 participants at wave two, 2128 (99.5%) provided data on ecstasy use of whom 
227 (10.7%) reported use of sleep medications. Of the 1978 participants at wave three, 1977 
(99.9%) provided ecstasy data (658, 33% ever used: 1319, 67% never used), of whom 239 
(12.1%) used sleep medications. At both waves, of those who had ever used ecstasy, a greater 
proportion were male, only had high school education, were employed, had never been 
married, had higher trauma scores and a greater proportion used sleep medications. They also 
had a greater proportion reporting current tobacco, cannabis and meth/amphetamine use and 
were classified as hazardous alcohol consumers (Table 1). Participants could record multiple 
types of sleeping medications or aids, with the most frequently reported at both waves being 
benzodiazepines (or other hypnotics), herbal remedies, and antihistamines (Table 2). Notably, 
a greater percentage of ecstasy users reported the use of benzodiazepines at both waves, 
compared to non-ecstasy users. Finally, there were significant  correlations between all types 
of substances used, in particular ecstasy and meth/amphetamine (Spearman’s rho wave two 
.708: wave three .693) (online Appendix B). 
Table 2 here 
 
Table 3 shows the GEE model on the left hand side. The odds of using sleep medications was 
increased for females (odds ratio (OR) = 1.44 95% confidence interval (CI) 1.13, 1.84) and 
for those who were classified as having depression (OR = 1.88 95% CI 1.39, 2.53). Each 
major trauma increased the odds of sleeping medication use by 19% (95% CI 1.12, 1.26). The 
association between >monthly ecstasy (versus never) (OR = 1.10) and sleep medication was 
not significant.  Those who used meth/amphetamine >monthly versus never had increased 
odds of sleep medication use (OR = 3.03, 95% CI 1.30, 7.03). In addition, >monthly cannabis 
use (versus never) (OR = 1.78 95% CI 1.05, 3.01) was associated with an increased odds of 
using sleeping medications. Logistic regression of wave two data on wave three sleeping 
medication showed that none of the substance use variables were significant predictors, but 
that gender (OR = 1.37), depression (OR = 1.65) and trauma (OR = 1.17) remained 
significant predictors (Table 3 right hand side).  
Table 3 here 
 
Two sensitivity analyses were conducted. The first restricted sleep medications to 
‘pharmacist only’ or prescription medications, defined as benzodiazepines (or other 
hypnotics), antihistamines, and analgesics combined with antihistamines. This analysis was 
conducted to determine whether the above findings were biased by the inclusion of non-
specific or less effective products. There were 85 (4.0%) people using these at wave two and 
115 (5.8%) at wave three. In replicating the earlier analytic plan, ecstasy use was still not  
significantly related to the use of sleep medication. Meth/amphetamine produced similar 
results to those of the main analysis (>monthly OR = 4.18), with gender (female OR = 1.63) 
and depression (OR = 1.94) significantly increasing the odds of using sleep medications, 
while each additional trauma increased the odds by 24%. The second sensitivity analysis 
excluded participants with missing data on the frequency of meth/amphetamine use at wave 
three (Table 4, right hand half). The results were similar to those in the main analysis. 
Table 4 here 
 
Discussion 
Data from animal studies have shown that the use of MDMA (‘ecstasy’) disrupts sleep 
patterns over an extended period (19). However, findings from human ecstasy users are 
equivocal with studies finding increases and decreases in sleep (16, 34). Furthermore, data 
from naturalistic settings have typically recruited purposefully sampled groups or 
convenience samples and even where poly-drug use has been accounted for in analyses, the 
effects of different drug classes are not examined separately (21). This study makes an 
important contribution through its employment of a general population sample to assess the 
relationship between the use of ecstasy and sleep problems, indexed as the use of sleeping 
medications (pharmaceutical or other substances) while controlling for other key factors. 
Univariate statistics showed that ecstasy users reported greater rates of sleep medication use. 
However, multivariate models found no increased odds of sleep medication use for ecstasy 
users compared to non-users, when their use of other drugs was accounted for. Use of 
meth/amphetamine or cannabis were associated with a greater likelihood of sleeping 
medication use in these models. These findings were largely replicated in a sensitivity 
analysis restricted to prescription or pharmacist only sleeping medications.  
 
Poly-drug use is prevalent amongst ecstasy consumers (10-11, 35) and is one of the limiting 
factors in translating data from animal models involving MDMA to human ecstasy users. In 
the present study, people who used meth/amphetamine monthly or more had three times the 
odds of using any sleeping medication and four times the odds of using a prescription or 
pharmacist only medication. Amphetamine-induced sleep disorder with insomnia in the acute 
phase and hypersomnia during withdrawal is well characterised (12). However, after a few 
days of hypersomnia, insomnia is likely, continuing at least until 20 days (23). Given this 
disruption, the use of sleeping medications is unsurprising following the use of 
meth/amphetamine in either the immediate aftermath or to cope with persistent insomnia. 
 
The absence of a significant relationship between ecstasy and sleeping medication use once 
other drug use was accounted for indicates that the higher rates of sleeping medication 
reported amongst ecstasy users in our community sample is attributable to the greater use of 
methamphetamines and/or cannabis also observed amongst this group. It is worth noting, 
however, that this is a statistical finding and does not rule out the possibility that (some) 
ecstasy users do take sleeping medications to address the effects of this drug. However, the 
use of other drugs that are more strongly associated with sleep medication use amongst this 
group means that it not possible to definitively identify which drug may lead to medication 
consumption. Further, the absence of a multivariate association between ecstasy use and sleep 
medication use is an important finding and contribution to the literature as it demonstrates the 
importance of measuring and controlling for poly-drug use. Inability to do so may lead to 
erroneous conclusions about sleeping problems amongst ecstasy users.   
 
The use of sleeping medications was also associated with: being female, being categorised 
with depression and life-time traumatic events. Reasons for the higher prevalence of sleeping 
problems among women (36) is not clearly understood, but both lifespan and menstrual 
fluctuations in hormones levels have been implicated (37). The relationship between sleep 
disturbance, traumatic events and mental health problems is complex, with insomnia 
associated with the risk of developing depression (38); pre-existing sleep disturbance being a 
risk factor for the development of mental health problems following traumatic events (39) 
and traumatic events disrupting sleep (40). Thus, the triumvirate of non-substance use risk 
factors reported in the current study are consistent with the literature. 
  
The consumption of sleeping medications was used as a proxy for sleep disturbance in this 
study. The BPHQ (which was included as a covariate in our models) contains two items 
pertaining to sleep (‘Trouble falling or staying asleep, or sleeping too much’ and ‘Feeling 
tired or having little energy’). Thus, it is possible that the inclusion of the BPHQ as a measure 
of depression may mask some of the relationship between meth/amphetamine use, or indeed 
ecstasy use, and sleeping medications. A sensitivity analysis (results not shown) removing the 
BPHQ from the model marginally increased the odds ratio for meth/amphetamine but not for 
ecstasy, reinforcing the interpretation that the extent of sleep disruption for ecstasy users in 
this group was not severe. 
 
There are a number of limitations associated with this study. First, sleep disruption was not 
directly assessed either with self-report measures or polysonography. However, even self-
reported sleep data is not without criticisms (41). Second, the temporal relationship between 
drug use and sleep medication cannot be guaranteed. The use of sleeping medications in the 
PATH study had a reference period of the last month and substance use data was collected for 
the last year. Thus, whilst it is likely that the latter was consumed first, the length of time 
between drug use and sleep medication use may vary. That is, it was monthly or more 
frequent use or that was associated with the use of sleeping medications, but it is unknown if 
this was during the acute phase or during a later period when sleep disruptions may persist. 
Third, the purity and presents of adulterants in the ecstasy is unknown. Street ‘ecstasy’ may 
contain little or no MDMA and instead maybe a mixture of meth/amphetamine, ketamine and 
other substances (42). Over the period 2003-2008, the purity of Australian drug seizures for 
this class of drugs remained relatively stable, although the proportion of ecstasy users in the 
ACT reporting ‘high’ purity declined (43-44). Thus, these findings may not generalise to 
settings with different purity formulations of ecstasy. Four, the missing frequency data on 
258 meth/amphetamine users at wave three represent 43% of those using this substance. If all 
these cases were >monthly users, the magnitude of the OR would be reduced but still 
significant: if they were all infrequent users, this category would still not be significant 
(analysis not shown). Nevertheless, these shortcoming should not negate the importance of 
data collected from a representative community cohort in contrast to the previous 
overreliance on snowballing and purposive recruitment (18). 
Conclusion 
Animal models show long-term disruption of sleep following exposure to MDMA. The 
present study is one of few to examine this relationship in a representative general 
community sample, and the first to account for concurrent use of other drugs associated with 
sleeping problems that are commonly consumed by ecstasy users. We found that ecstasy use 
was not associated with the use of sleeping medications when other drug use was accounted 
for. There was, however, a strong relationship between the use of meth/amphetamine and 
sleep medication. Future studies must measure and account for this association to avoid 
misinterpretation of the univariate link between ecstasy use and poor sleep. 
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Table 1: Participant characteristics, sub-divided by ecstasy use status at wave two and wave three 
Variable Ecstasy: never 
used  
(n = 1459: 69%) 
Ecstasy: ever 
used  
(n = 669: 21%) 
Statistic Ecstasy: never 
used 
(n = 1319: 67%) 
Ecstasy: ever 
used 
(n = 658: 23%) 
Statistic 
  Wave 2   Wave 3  
Gender  female n (%) 
 male n (%) 
823 (56) 
636(44) 
297 (44) 
372 (56) 
χ2 26.6 (1) 
p<.001 
743 (56) 
576 (44) 
314 (48) 
344(52) 
χ2 13.1 (1) 
p<.001 
Education high school n (%) 
 post school n (%) 
 tertiary n (%) 
257 (18) 
541 (37) 
659 (45) 
151 (23) 
239 (36) 
279 (42) 
χ2 7.4 (2) 
p=.025 
156 (12) 
496 (38) 
646 (50) 
116 (18) 
248 (38) 
281 (44) 
χ2 14.4 (2) 
p=.001 
Employment full or part time n (%) 
 want more work/unemployed n (%) 
 not in the labour force n (%) 
1259 (86) 
68 (5) 
132 (9) 
587 (88) 
43 (6) 
39 (6) 
χ2 8.6 (2) 
p=.012 
2438 (88) 
94 (3) 
246 (9) 
1179 (89) 
71 (5) 
77 (6) 
χ2 13.1 (2) 
p=.001 
Ever married/de facto yes n (%) 521 (36) 101 (15) χ2 94.6 (1) 
p<.001 
762 (58) 241 (37) χ2 78.8 (1) 
p<.001 
BPHQ  major or other n (%) 148 (10) 92 (14) χ2 6.0 (1) 
p=.015 
127 (10) 58 (9) χ2 0.4 (1) 
p=.555 
Lifetime trauma  mean (SD) 1.2 (1.4) 1.5 (1.6) t 4.2 (2089) 
p<.001 
1.8 (1.8) 2.0 (1.9) t 2.7 (1870) 
p=.007 
Sleep medications  yes n (%) 131 (9) 96 (14) χ2 13.8 (1) 
p<.001 
141 (11) 98 (15) χ2 7.3 (1) 
p=.007 
Hazardous alcohol a  yes n (%) 279 (19) 324 (49) χ2 193.7 (1) 
p<.001 
194 (15) 284 (44) χ2 197.0 (1) 
p<.001 
Tobacco never n (%) 
 former n (%) 
979 (67) 
198 (14) 
245 (37) 
121 (18) 
χ2 192.5 (2) 900 (68) 
228 (17) 
261 (40) 
175 (27) 
χ2 157.6 (2) 
 current n (%) 281 (19) 302 (45) p<.001 191 (15) 222 (34) p<.001 
Cannabis never n (%) 
 not current user n (%) 
 infrequent user n (%) 
 >monthly user n (%) 
 507 (35) 
815 (56) 
101 (7) 
31 (2) 
7 (1) 
303 (46) 
184 (27) 
173 (26) 
χ2 640.0 (3) 
p<.001 
438 (33) 
809 (62) 
33 (3) 
33 (3) 
9 (1) 
442 (67) 
123 (19) 
82 (13) 
χ2 419.7 (3) 
p<.001 
Meth/amphetamine never n (%) 
 not current user n (%) 
 infrequent user n (%) 
 >monthly user n (%) 
 unknown frequency n (%) 
1338 (94) 
80 (6) 
11 (<1) 
0 (0) 
- 
201 (30) 
256 (38) 
169 (25) 
42 (6) 
- 
χ2 982.6 (3) 
p<.001 
1202 (91) 
114 (9) 
2 (<1) 
1 (<1) 
0 (0) 
174 (27) 
127 (19) 
85 (13) 
13 (2) 
258 (39) 
χ2 1007.5 (3) 
p<.001 
Ecstasy never n (%) 
 not current user n (%) 
 infrequent user n (%) 
 >monthly user n (%) 
1459 (100) 
- 
- 
- 
- 
353 (53) 
247 (37) 
69 (10) 
Not assessed 1319 (100) 
- 
- 
- 
- 
477 (73) 
163 (25) 
18 (3) 
Not assessed 
a AUDIT score >8 = hazardous:  BPHQ = Brief Patient Health Questionnaire classified with major or other depression. 
Not current user = not in the last 12 months: Infrequent user = in the last 12 months but less than monthly use 
Missing data wave two: gender 0: education 2: employment 0: married 2: BPHQ 13: lifetime trauma 37: sleep medications 1: alcohol 12: tobacco 2: cannabis 7: 
Meth/amphetamine 1  
Missing data wave three: gender 0: education 34: employment 0: married 1: BPHQ 10: lifetime trauma 105: sleep medications 1: alcohol 39: tobacco 0: cannabis 8: 
Meth/amphetamine 1 
 
  
Table 2 Sleeping aids reported at wave two (n = 227) and at wave three (n = 239): multiple substances could be recorded 
 
Categories Ecstasy: never used 
n=131 
Wave 2 
Ecstasy: ever used 
n=96 
Wave 2 
Ecstasy: never used 
n=141 
Wave 3 
Ecstasy: ever used 
n=98 
Wave 3 
Antidepressants n (%) 5 (3) 0 (0) 5 (3) 0 (0) 
Antihistamines n (%) 17 (10) 12 (9) 30 (17) 7 (6) 
Antihistamines + Analgesics n (%) 7 (4) 1 (1) 4 (3) 7 (6) 
Benzodiazepines or other hypnotics a n (%) 28 (17) 38 (28) 30 (17) 31 (27) 
Cannabis &/or alcohol n (%) 0 (0) 5 (4) 2 (1) 2 (2) 
“Cold & ‘flu” medication n (%) 4 (2) 4 (3) 5 (3) 0 (0) 
Magnesium &/or calcium supplement n (%) 2 (1) 3 (2) 4 (2) 4 (3) 
Melatonin n (%) 1 (1) 1 (1) 1 (1) 3 (3) 
Other analgesics n (%) 22 (13) 6 (5) 13 (7) 9 (8) 
Other herbal n (%) 34 (21) 30 (23) 34 (19) 17 (15) 
Valerian n (%) 32 (20) 24 (18) 32 (18) 15 (13) 
Other n (%) 12 (7) 9 (7) 6 (3) 7 (6) 
Total substances n 164 133 175 116 
 
Generic & trademark brands named in each category  
Antihistamines: Dozile, Doxylamine Succinate, Phenergan, Polaramine, Restavit, 
Antihistamine + Analgesic: Dolased, Mersyndol  
Benzodiazepines: Alodorm, Mogadon, Normison, Serpax, Temazepam, Temaze, Temtabs, Valium, Xanax  
Other analgesics: Ibuprofen, Naproxen, Nurophen, Paracetamol, Panadine Forte, Panadol, Tylenol 
Other herbal includes: Camomile tea, Chinese herbal medicine, lavender, ‘tranquil night’ tablets 
a  “Stilnox or Imovane”  
 
 
Table 3: Predictors of sleeping medication use at waves two and three (left hand side, 
generalised estimating equation GEE model: n=2082) and predictors of wave three sleeping 
medications from wave two data (right hand side, logistic regression: n=1852) 
Variable  (reference group)  GEE  Logistic Regression 
  p value B 95 % CI  p value B 95 % CI 
Gender  (male) .004 1.44 1.13-1.84 .041 1.37 1.01, 1.86 
Education  Tertiary 
 Post-school 
 (<high school certificate) 
.468 
.876 
1.13 
0.98 
0.82-1.55
0.72-1.33 
.841 
.231 
0.96 
0.78 
0.53, 1.17
0.65, 1.43 
Employment Not in labour force 
 P-T want more work/unemployed 
 (full-time/part-time) 
.737 
.134 
0.93 
1.40 
0.62-1.40
0.90-2.19 
.671 
.227 
0.88 
1.43 
0.49, 1.58
0.80, 2.57 
Ever married /de facto (yes) .158 1.19 0.94-1.51 .166 1.28 0.90, 1.80 
Depression (no) <.001 1.88 1.39-2.53 .015 1.65 1.10, 2.47 
Lifetime trauma  (none) <.001 1.19 1.12-1.26 .002 1.17 1.06, 1.28 
Hazardous alcohol (no) .132 1.22 0.94-1.58 .652 1.08 0.77, 1.53 
Tobacco Current 
 Former 
 (never) 
.172 
.742 
1.24 
0.95 
0.91-1.69
0.68-1.31 
.370 
.163 
1.19 
1.34 
0.81, 1.75
0.89, 2.03 
Cannabis >monthly 
 infrequent 
 not current 
 (never) 
.031 
.868 
.077 
1.78 
1.04 
1.36 
1.05-3.01
0.64-1.70
0.97-1.91 
.598 
.984 
.547 
1.20 
0.99 
1.14 
0.61, 2.36
0.55, 1.79
0.74, 1.75 
Ecstasy >monthly  
 infrequent 
 not current 
 (never) 
.834 
.556 
.681 
1.10 
1.16 
0.93 
0.47-2.54
0.71-1.90
0.65-1.32 
.250 
.095 
.093 
1.80 
1.64 
1.46 
0.66, 4.90
0.92, 2.94
0.94, 2.27 
Meth/amphetamine  >monthly 
 infrequent 
 frequency unknown 
 not current 
 (never) 
.010 
.465 
.026 
.640 
 
3.03 
1.23 
1.70 
1.09 
1.30-7.03
0.71-2.15
1.07-2.71
0.75-1.59 
 0.82 
0.96 
-- 
0.85 
0.24, 2.79
0.50, 1.82
-- 
0.53, 1.35 
PT = part-time: Goodness of fit quasi likelihood criterion:  2583.65 
 
 Table 4 Sensitivity analyses a) for use of prescription or pharmacist only sleeping medications (left half of table n=2082) and b) excluding those 
with unknown frequency of meth/amphetamine use at wave three (right half n=2079). 
Variable  (reference group)  p value B 95 % CI  p value B 95 % CI 
 Prescription / pharmacist only Excluding 258 unknown frequency cases 
Gender  (male) .006 1.63 1.05-2.32 .002 1.50 1.15-1.89 
Depression (no) .001 1.94 1.31-2.87 <.001 1.77 1.32-2.46 
Lifetime trauma  (no) <.001 1.24 1.15-1.34 <.001 1.27 1.34-2.33 
Meth/amphetamine >monthly 
 infrequent 
 frequency unknown 
 not current 
 (never) 
.020 
.993 
.177 
.906 
 
4.18 
1.00 
1.60 
0.97 
1.25-13.99 
0.41-2.48 
0.81-3.18 
0.55-1.70 
.010 
.524 
-- 
.662 
3.08 
1.20 
-- 
1.09 
1.31-7.27 
0.68-2.13 
-- 
0.74-1.60 
Model (a) included all the variables from table 3. Goodness of fit quasi likelihood criterion: 1447.24:  
Model (b) included all the variables from table 3. Goodness of fit quasi likelihood criterion: 2388.20 
  
Appendix B (online supplement) 
Spearman’s correlation coefficients between each category of substances reported. Below the diagonal are results from wave two: above the 
diagonal from wave three 
 
 Alcohol Tobacco Cannabis Ecstasy Meth/amphetamine Sleep medications 
Alcohol  .267 .303 .350 .297 .075 p=.001 
Tobacco .209  .435 .291 .367 .071 p=.002 
Cannabis .336 .441  .476 .464 .068 p=.003 
Ecstasy .333 .300 .555  .693 .062 p=.006 
Meth/amphetamine .313 .370 .552 .708  .078 p=.001 
Sleep medications .065 p=.003 .123 .111 .092 .118  
All p values <.001 except as marked 
Categories: alcohol (Hazardous use yes/no), tobacco (current, former, never), cannabis (> monthly, infrequent, former, never), ecstasy (> monthly, infrequent, former, never),  
meth/amphetamine (wave two: > monthly, infrequent, former, never) (wave three:frequency unknown, > monthly, infrequent, former, never) 
